Enhertu

Product NDC
65597-406
11-digit product format
655970406
Labeler code
65597
Product ID
65597-406_50272b50-1dd2-49a0-a74e-e6e182decb79
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
fam-trastuzumab deruxtecan-nxki
Dosage form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS
Labeler
Daiichi Sankyo Inc.
Application
BLA761139
Marketing category
BLA
Marketing start
2019-12-20
Substance
TRASTUZUMAB DERUXTECAN
Active strength
100 mg/5mL
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
EnhertuFAM-TRASTUZUMAB DERUXTECAN-NXKIDaiichi Sankyo Inc.7e67e73e-ddf4-4e4d-8b50-09d7514910b62026-05-15Boxed warning, Warnings, Adverse reactionsExact identifier

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

boxed warning

WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY Interstitial Lung Disease (ILD) and pneumonitis, including severe, life-threatening, and fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and the need to immediately report symptoms [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) ] . Embryo-Fetal Toxicity: Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception [see Warnings and Precautions (5.4) , Use in Specific Populations (8.1 , 8.3) ] . WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Interstitial lung disease (ILD) and pneumonitis, including severe, life threatening, and fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms. ( 2.3 , 5.1 ) Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception. ( 5.4 , 8.1 , 8.3 )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Neutropenia: Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. Manage through treatment interruption or dose reduction. ( 2.3 , 5.2 ) Left Ventricular Dysfunction (LVD): Assess left ventricular ejection fraction (LVEF) prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated. Manage through treatment interruption or discontinuation. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure (CHF). ( 2.3 , 5.3 ) 5.1 Interstitial Lung Disease/Pneumonitis Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU [see Adverse Reactions (6.1) ] . A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment. Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic (Grade 1) ILD, consider corticosteroid treatment (e.g., ≥0.5 mg/kg/day prednisolone or equivalent). Withhold ENHERTU until recovery [see Dosage and Administration (2.3) ] . In cases of symptomatic ILD (Grade 2 or greater), promptly initiate systemic corticosteroid treatment (e.g., ≥1 mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks. Permanently discontinue ENHERTU in patients who are diagnosed with symptomatic (Grade 2 or greater) ILD [see Dosage and Administration (2.3) ] . HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg) ENHERTU as Monotherapy In patients treated with ENHERTU 5.4 mg/kg, ILD occurred in 12% of patients. Median time to first onset was 5.5 months (range: 0.9 to 31.5). Fatal outcomes due to ILD and/or pneumonitis occurred in 0.9% of patients treated with ENHERTU. ENHERTU in Combination with Pertuzumab In patients treated with ENHERTU 5.4 mg/kg in combination with pertuzumab (N=431), ILD occurred in 12% of patients. Median time to first onset was 8.0 months (range: 0.6 to 33.8). Fatal outcomes due to ILD a...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5.1) ] Neutropenia [see Warnings and Precautions (5.2) ] Left Ventricular Dysfunction [see Warnings and Precautions (5.3) ] The most common adverse reactions (≥20%), including laboratory abnormalities, in patients with: HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer, HER2-Mutant NSCLC, and HER2-Positive (including IHC 3+) Solid Tumors are decreased white blood cell count, nausea, decreased hemoglobin, decreased neutrophil count, decreased lymphocyte count, fatigue, decreased platelet count, increased aspartate aminotransferase, increased alanine aminotransferase, increased blood alkaline phosphatase, vomiting, alopecia, constipation, decreased blood potassium, decreased appetite, diarrhea, and musculoskeletal pain. ( 6.1 ) HER2-Positive Early Breast Cancer are decreased hemoglobin, increased alanine aminotransferase, increased aspartate aminotransferase, decreased white blood cell count, nausea, peripheral neuropathy, diarrhea, decreased neutrophil count, alopecia, fatigue, decreased lymphocyte count, rash, musculoskeletal pain, decreased blood potassium, constipation, vomiting, stomatitis, and decreased appetite. ( 6.1 ) HER2-Positive Metastatic Breast Cancer in Combination with Pertuzumab are decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, nausea, increased alanine aminotransferase, diarrhea, increased aspartate aminotransferase, decreased lymphocyte count, decreased platelet count, increased blood alkaline phosphatase, decreased blood potassium, fatigue, alopecia, vomiting, upper respiratory tract infection, constipation, decreased appetite, decreased weight, COVID-19, musculoskeletal pain, increased blood bilirubin, and abdominal pain. ( 6.1 ) HER2-Positive Gastric Cancer are decreased hemoglobin, decreased white blood cell count, decreased neutrophil count, decreased lymphocyte count, decreased platelet count, nausea, decreased appetite, increased aspartate aminotransferase, fatigue, increased blood alkaline phosphatase, increased alanine aminotransferase, diarrhea, decreased blood potassium, vomiting, constipation, increased blood bilirubin, pyrexia, and alopecia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Daii...

adverse reactions table

Table 4: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) Patients in DESTINY-Breast11Adverse ReactionsENHERTU 5.4 mg/kg followed by THP N = 320ddAC followed by THP N = 312All Grades %Grade 3 or 4 %All Grades %Grade 3 or 4 %THP= paclitaxel, trastuzumab, and pertuzumab; ddAC=dose dense doxorubicin and cyclophosphamide; Events were graded using NCI CTCAE version 5.0.Gastrointestinal DisordersNausea651.9520.3Diarrhea596543.2Constipation290.3240Vomiting290.9210.6Stomatitis Including aphthous ulcer, cheilitis, glossitis, mouth ulceration, mucosal inflammation, and stomatitis.230.3361.0Abdominal painIncluding abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, and gastrointestinal pain.160120Nervous System DisordersPeripheral neuropathyIncluding dysesthesia, hypoesthesia, neuropathy peripheral, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy.592.5472.2HeadacheIncluding headache, migraine, and sinus headache. 180160Skin and Subcutaneous Tissue DisordersAlopecia480490RashIncluding dermatitis, dermatitis acneiform, dermatitis bullous, eczema, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, skin exfoliation, and urticarial dermatitis.310.9251.0General Disorders and Administration Site ConditionsFatigueIncluding asthenia, fatigue, and malaise.410.6552.2Musculoskeletal and Connective Tissue DisordersMusculoskeletal painIncluding arthralgia, back pain, bone pain, muscle spasms, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, and pain in extremity.300280.3Metabolism and Nutrition DisordersDecreased appetite200180.3Respiratory, Thoracic and Mediastinal DisordersEpistaxis150100Cough100140Infections and InfestationsUpper respiratory tract infectionIncluding influenza, influenza-like illness, laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, and upper respiratory tract infection.130.6200.3COVID-19100.9110.3

Additional Listing Data#

Finished product
Yes
Brand name base
Enhertu
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
TRASTUZUMAB DERUXTECAN100 mg/5mL

Harmonized Identifiers#

Field, Values table
FieldValues
Unii5384HK7574
Rxcui2267576, 2267581

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
7195b158-8eea-4ef1-aa71-d7f22e2af1c4Product name120200604
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
65597-406-012024-02-05C16284748780-11030e365-11f4-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use ENHERTU safely and effectively. See full prescribing information for ENHERTU. ENHERTU ® (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U.S. Approval: 2019
65597-406-012024-02-05C16284748780-11030e365-11f4-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use ENHERTU safely and effectively. See full prescribing information for ENHERTU. ENHERTU ® (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U.S. Approval: 2019
65597-406-012024-02-05C16284748780-11030e365-11f4-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use ENHERTU safely and effectively. See full prescribing information for ENHERTU. ENHERTU ® (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U.S. Approval: 2019
65597-406-012024-01-30C16284748780-11030e365-11f4-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use ENHERTU safely and effectively. See full prescribing information for ENHERTU. ENHERTU ® (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U.S. Approval: 2019
65597-406-012024-01-30C16284748780-11030e365-11f4-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use ENHERTU safely and effectively. See full prescribing information for ENHERTU. ENHERTU ® (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U.S. Approval: 2019
65597-406-012024-01-30C16284748780-11030e365-11f4-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use ENHERTU safely and effectively. See full prescribing information for ENHERTU. ENHERTU ® (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U.S. Approval: 2019

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
65597-406-01Enhertu1 in 1 CARTONINJECTION, POWDER, LYOPHILIZED,128
65597-406-01Enhertu5 mL in 1 VIAL, SINGLE-DOSEINJECTION, POWDER, LYOPHILIZED,528

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
65597-406-01EA - Each65597-4069bfdad47-da53-43a9-a828-f8407e110abe12020-01-03

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
65597-406ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [DAIICHI SANKYO INC.]21Current NDC, Legacy NDC, 2 package rows20250522_7e67e73e-ddf4-4e4d-8b50-09d7514910b6.zip

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761139Enhertufam-trastuzumab deruxtecan-nxki351(a)Rx2026-06-01

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
2267581ENHERTU 100 MG InjectionPSN7e67e73e-ddf4-4e4d-8b50-09d7514910b628
2267576fam-trastuzumab deruxtecan-nxki 100 MG InjectionPSN7e67e73e-ddf4-4e4d-8b50-09d7514910b628
2267581fam-trastuzumab deruxtecan-nxki 100 MG Injection [Enhertu]SBD7e67e73e-ddf4-4e4d-8b50-09d7514910b628
2267576fam-trastuzumab deruxtecan-nxki 100 MG InjectionSCD7e67e73e-ddf4-4e4d-8b50-09d7514910b628
2267581Enhertu 100 MG InjectionSY7e67e73e-ddf4-4e4d-8b50-09d7514910b628

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startMarketing endSampleExclude flagStatus
65597-406-01655970406011 VIAL, SINGLE-DOSE in 1 CARTON (65597-406-01) / 5 mL in 1 VIAL, SINGLE-DOSE2019-12-200000-00-00NoNoCurrent